TYK Medicines RET Kinase Inhibitor Compound Patent EP3974422A1
Summary
The European Patent Office published patent EP3974422A1, granting TYK Medicines Inc. protection for a heterocyclic compound for use as a RET kinase inhibitor. The patent names five inventors and covers the compound as a pharmaceutical composition for treating diseases associated with RET kinase activity. This grant provides TYK Medicines exclusive rights to the RET kinase inhibitor technology in designated European member states.
Pharmaceutical companies developing kinase inhibitors targeting RET-driven cancers should review freedom-to-operate positions and assess potential licensing needs. Generic drug manufacturers may also wish to evaluate the patent's claims landscape for future entry strategies.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 31 changes logged to date.
What changed
The European Patent Office published patent EP3974422A1, granting TYK Medicines Inc. exclusive rights to a heterocyclic compound for use as a RET kinase inhibitor. The patent names inventors Jun Li, Maolin Zheng, Chengshan Niu, Apeng Liang, and Yusheng Wu, and covers the compound as a pharmaceutical composition for treating diseases associated with RET kinase activity.
Pharmaceutical companies developing kinase inhibitors targeting RET-driven cancers should review freedom-to-operate positions and assess potential licensing needs. Generic drug manufacturers may also wish to evaluate the patent's claims landscape for future entry strategies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF
Publication EP3974422A1 Kind: A1 Apr 15, 2026
Applicants
TYK Medicines, Inc.
Inventors
LI, Jun, ZHENG, Maolin, NIU, Chengshan, LIANG, Apeng, WU, Yusheng
IPC Classifications
C07D 401/14 20060101AFI20221223BHEP C07D 403/14 20060101ALI20221223BHEP C07D 475/08 20060101ALI20221223BHEP C07D 498/04 20060101ALI20221223BHEP C07D 413/14 20060101ALI20221223BHEP C07D 471/04 20060101ALI20221223BHEP C07D 473/34 20060101ALI20221223BHEP C07D 487/04 20060101ALI20221223BHEP C07D 491/048 20060101ALI20221223BHEP C07D 513/04 20060101ALI20221223BHEP A61P 35/00 20060101ALI20221223BHEP C07D 491/056 20060101ALI20221223BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.